PF-07220060 is under clinical development by Pfizer and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PF-07220060’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PF-07220060 is under development for the treatment of solid tumors including liposarcoma, prostate cancer, metastatic breast cancer, HER2 positive breast cancer and HER2 negative breast cancer, colorectal cancer (CRC) and adenocarcinoma of non-small cell lung cancer (NSCLC). It is administered through oral route. The drug candidate acts by targeting CDK4.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of PF-07220060’s drug-specific PTSR and LoA scores, buy the report here.